Skip to content
MARKETS / NYSE / CVM
NYSE · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

CEL SCI Corp. CVM

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$-25.4M
$-17.2M
In brief

What this company does

CEL-SCI is currently focused on the development of the following product candidates and technologies with an emphasis on Multikine: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; and 2) L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology, or LEAPS, with several product candidates under development for the potential treatment of rheumatoid arthritis. None of CEL-SCI's product candidates have been approved for sale, barter or exchange by the Food and Drug Administration (FDA) or any other regulatory agency for any use to treat disease in humans nor has the safety or efficacy of these products been established for any use. CEL-SCI was formed as a Colorado corporation in 1983. CEL-SCI's principal office is located at 8229 Boone Boulevard, Suite 802, Vienna, VA 22182. CEL-SCI's patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses "heteroconjugates" to direct the body to choose a specific immune response. Patents and other proprietary rights are essential to CEL-SCI's business. If commercial approval is obtained, CEL-SCI intends to manufacture Multikine in a proprietary manner in CEL-SCI's manufacturing facility near Baltimore, Maryland, USA.

Written from the business description in Cel-Sci Corporation's annual report to the U.S. Securities and Exchange Commission, filed 29 December 2025. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2014 · Revenue 0.3 · Net income -27.4
-10M-20M200920112013201520172019202120232025
Compound annual growth
−34.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2014 · Operating -9721.4% · Net -10359.6%
-5000%-10000%200920112013201520172019202120232025
ROE
FY2025 · ROE -176.3%
-500%-1000%200920112013201520172019202120232025

Each USD of equity lost 176 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -17.2
-10M-20M200920112013201520172019202120232025

Total assetsUSD 28.2M
EquityUSD 16.0M
CashUSD 11.0M
Gross debtUSD 5.7M
Net debtUSD -5.3M
Current ratio2.26×

The company holds more cash than debt.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B···········0.00.00.00.0··
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B·················
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−6.27−15.31−0.73−0.87−0.90−0.82−0.71−1.87−1.91−2.37−10.51−12.21−0.66−0.78−1.490.06−0.31
Dividend / sh $·················
Payout %·················
ROE %−176.3−206.4−142.6−82.8−95.4−243.4−862.2···−1152.3−312.9−133.6−192.2−139.257.1−462.7
Shares out B0.010.000.050.040.040.040.040.030.010.010.000.080.030.030.210.20·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 10 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNYSE
Incorporated inColorado
Fiscal year endsSeptember 30
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image